Haematopoietic stem cell transplantation: indications, clinical developments and future directions

Bibliography

• REIFFERS J, GASPARD MH, MARANINCHI D et al.: Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br. Haematol (1989) 72:57–63.
   PubMed Web of Science ®Google Scholar
• ZITTOUN RA, MANDELLI F, WILLEMZE R et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italian° Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl. I Med. (1995) 332:217–223.
   Google Scholar
• BIGGS JC, HOROWITZ MM, GALE RP et al.: Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood (1992) 80:1090–1093.
   PubMed Web of Science ®Google Scholar
• GRIM WADE D, WALKER H, OLIVER F et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood (1998) 92:2322–2333.
   Google Scholar
• •This study highlights the importance of diagnostic cytogenetics as an independent prognostic factor in AML.
   Google Scholar
• SLOVAK ML, KOPECKY KJ, CASSILETH PA et al.: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood (2000) 96:4075–4083.
   PubMed Web of Science ®Google Scholar
• APPELBAUM FR, ROWE JM, RADICH J, DICK JE: Acute myeloid leukemia. Hematology (Am. Soc. Hematol Educ. Program) (2001):62–86.
   PubMedGoogle Scholar
• BURNETT AK, GOLDSTONE AH, STEVENS RM et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet (1998) 351:700–708.
   Google Scholar
• BARRETT AJ, HOROWITZ MM, POLLOCK BH et al: Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl. Med. (1994) 331:1253–1258.
   PubMed Web of Science ®Google Scholar
• THIEBAUT A, VERNANT JP, DEGOS L et al.: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin. North Am. (2000) 14:1353-1366, x.
   Google Scholar
• SIERRA J, STORER B, HANSEN JA et al: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood (1997) 89:4226–4235.
   PubMed Web of Science ®Google Scholar
• BIGGS JC, SZERJ, CRILLEY P et al.: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood(1992) 80:1352–1357.
   PubMedGoogle Scholar
• GALE RP, HEHLMANN R, ZHANG MJ et al.: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood (1998) 91:1810–1819.
   Google Scholar
• •A study that demonstrated a long-term advantage for HLA-identical sibling transplant over hydroxyurea or IFN inCML.
   Google Scholar
• DRUKER BJ: Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert. Opin. Pharmacother. (2003) 4:963–971.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the clinical use of irnatinib mesylate.
   Google Scholar
• PAVLETIC ZS, ARROWSMITH ER, BIERMAN PJ et al.: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. (2000) 25:717–722.
   PubMed Web of Science ®Google Scholar
• DONEY KC, CHAUNCEY T, APPELBAUM FR: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. (2002) 29:817–823.
   PubMed Web of Science ®Google Scholar
• DREGER P, BRAND R, HANSZ J et al:Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia (2003) 17:841–848.
   PubMed Web of Science ®Google Scholar
• KHOURI IF, KEATING MJ, VRIESENDORP HM et al.: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. Clin. Oncol (1994) 12:748–758.
   Google Scholar
• PAVLETIC ZS, BIERMAN PJ, VOSE JM et al.: High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann. Oncol (1998) 9:1023–1026.
   PubMed Web of Science ®Google Scholar
• CARELLA AM, CONGIU AM, GAOZZA E et al: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. I Clin. Oncol (1988) 6:1411–1416.
   PubMed Web of Science ®Google Scholar
• SWEETENHAM JW, CARELLA AM, TAGHIPOUR G et al: High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. .1. Clin. Oncol (1999) 17:3101–3109.
   Google Scholar
• HASENCLEVER D, DIEHL V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. (1998) 339:1506–1514.
   Google Scholar
• NADEMANEE A, MOLINA A, FUNG H et al.: High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission. Biol. Blood Marrow Transplant. (1999) 5:292–298.
   PubMedGoogle Scholar
• SHIPP MA, ABELOFF MD, ANTMAN KH et al.: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation. in Aggressive Non-Hodgkin's Lymphomas: report of the jury. Clin. Oncol (1999) 17:423–429.
   Google Scholar
• PHILIP T, GUGLIELMI C, HAGENBEEK A et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl. I Med. (1995) 333:1540–1545.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated that patients with NHL-treated with auto-BMTs have increased overall survival than patients treated with conventional chemotherapy.
   Google Scholar
• HAIOUN C, LEPAGE E, GISSELBRECHT C et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte..1. Clin. Oncol (1997) 15:1131–1137.
   Google Scholar
• VAN BESIEN K, SOBOCINSKI KA, ROWLINGS PA et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood (1998) 92:1832–1836.
   PubMed Web of Science ®Google Scholar
• LEVINE JE, HARRIS RE, LOBERIZA FR Jr et al.: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood (2003) 101:2476–2482.
   Google Scholar
• VERDONCK LF, DEKKER AW, LOKHORST HM, PETERSEN EJ, NIEUWENHUIS HK: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 90:4201–4205.
   PubMed Web of Science ®Google Scholar
• VESOLE DH, TRICOT G, JAGANNATH S et al.: Autotransplants in multiple myeloma: what have we learned? Blood (1996) 88:838–847.
   Google Scholar
• ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl. I Med. (1996) 335:91–97.
   PubMed Web of Science ®Google Scholar
• ••A randomised study demonstratingimproved survival in patients receiving high-dose therapy combined with transplantation.
   Google Scholar
• BJORKSTRAND BB, LJUNGMAN P, SVENSSON H et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood (1996) 88:4711–4718.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, MOLINA AJ, SAHEBI F et al.: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of multiple myeloma. Blood (2003) 102:3447–3454.
   PubMed Web of Science ®Google Scholar
• ••Combination of auto- and allo-HSCT forpatients with multiple myeloma.
   Google Scholar
• GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079–2088.
   PubMed Web of Science ®Google Scholar
• •This study provides an improved method for evaluating the prognosis in MDS.
   Google Scholar
• DE WITTE T, HERMANS J, VOSSEN J et al.: Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acutemyeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. I Haematol (2000) 110:620–630.
   PubMed Web of Science ®Google Scholar
• PASSWEG JR, SOCIE G, HINTERBERGER W et al: Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood (1997) 90:858–864.
   PubMed Web of Science ®Google Scholar
• •A retrospective study demonstrating improved outcome of HLA-identical sibling bone marrow transplantation since 1976.
   Google Scholar
• DONEY K, LEISENRING W, STORB R, APPELBAUM FR: Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann. Intern. Med. (1997) 126:107–115.
   Google Scholar
• TYNDALL A, PASSWEG J, GRATWOHL A: Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann. Rheum. Dis. (2001) 60:702–707.
   PubMedGoogle Scholar
• •An update on the role of HSCT in autoirnmune diseases.
   Google Scholar
• RODENHUIS S, BONTENBAL M, BEEX LV et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl. I Med. (2003) 349:7–16.
   PubMed Web of Science ®Google Scholar
• BHATIA S, ABONOUR R, PORCU P et al.: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. I Clin. Oncol (2000) 18:3346–3351.
   PubMed Web of Science ®Google Scholar
• GRATWOHL A, BALDOMERO H, PASSWEG J, URBANO-ISPIZUA A: Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant. (2002) 30:813–831.
   PubMed Web of Science ®Google Scholar
• CHAMPLIN R, KHOURI I, KORNBLAU S, MOLLDREM J, GIRALT S: Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Carr: Opin. Omni (1999) 11:87–95.
   PubMedGoogle Scholar
• SLAVIN S, NAGLER A, NAPARSTEK Eet al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood (1998) 91:756–763.
   Google Scholar
• CHILDS R, CLAVE E, CONTENTIN N et al.: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 94:3234–3241.
   PubMed Web of Science ®Google Scholar
• HELDAL D, BRINCH L, TJONNFJORD G et al.: Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. Bone Marrow Transplant. (2003) 32:257–264.
   PubMed Web of Science ®Google Scholar
• HELDAL D, TJONNFJORD G, BRINCH L et al.: A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. (2000) 25:1129–1136.
   PubMed Web of Science ®Google Scholar
• POWLES R, MEHTA J, KULKARNI S et al.: Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 355:1231–1237.
   PubMed Web of Science ®Google Scholar
• COUBAN S, SIMPSON DR, BARNETT MJ et al.: A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (2002) 100:1525–1531.
   PubMed Web of Science ®Google Scholar
• BENSINGER WI, MARTIN PJ, STORER B et al.: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl. J. Med. (2001) 344:175–181.
   PubMed Web of Science ®Google Scholar
• CUTLER C, GIRT S, JEYAPALAN S et al: Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J. Clin. Oncol (2001) 19:3685–3691.
   PubMed Web of Science ®Google Scholar
• ••A meta-analysis of 16 studies comparingthe incidence of acute and chronic GVHD after PBST and BMT.
   Google Scholar
• FLOWERS ME, PARKER PM, JOHNSTON LJ et al.: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood (2002) 100:415–419.
   PubMed Web of Science ®Google Scholar
• ROCHA V, WAGNER JE Jr, SOBOCINSKI KA et al.: Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med. (2000) 342:1846–1854.
   Google Scholar
• •Recipient of umbilical cord blood transplant have lower incidence of acute and chronic GVHD.
   Google Scholar
• BARKER JN, DAVIES SM, DEFOR T et al.: Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood (2001) 97:2957–2961.
   PubMed Web of Science ®Google Scholar
• ROCHA V, CORNISH J, SIEVERS EL et al.: Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood (2001) 97:2962–2971.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN MJ, BARKER J, BAMBACH B et al.: Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl. J. Med. (2001) 344:1815–1822.
   PubMed Web of Science ®Google Scholar
• RATANATHARATHORN V, NASH RA, PRZEPIORKA D et al.: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood (1998) 92:2303–2314.
   PubMed Web of Science ®Google Scholar
• NASH RA, ANTIN JH, KARANES C et al.: Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 96:2062–2068.
   PubMed Web of Science ®Google Scholar
• HIRAOKA A, OHASHI Y, OKAMOTO S et al.: Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. (2001) 28:181–185.
   PubMed Web of Science ®Google Scholar
• BORNHAUSER M, SCHULER U, PORKSEN G et al: Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation (1999) 67:499–504.
   PubMedGoogle Scholar
• KIEHL MG, SCHAFER-ECKART K, KROGER M et al.: Mycophenolate mofetil for the prophylaxis of acute graft-versus- host disease in stem cell transplant recipients. Transplant. Proc. (2002) 34:2922–2924.
   PubMed Web of Science ®Google Scholar
• HALE G, ZHANG MJ, BUNJES D et al:Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood (1998) 92:4581–4590.
   PubMed Web of Science ®Google Scholar
• KOTTARIDIS PD, MILLIGAN DW, CHOPRA R et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96:2419–2425.
   PubMed Web of Science ®Google Scholar
• KOLB HJ, SCHATTENBERG A, GOLDMAN JM et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood (1995) 86:2041–2050.
   Google Scholar
• •Donor lymphocyte transfusion exert strong effects against myeloid forms of leukaemia and induces durable remissions in CML.
   Google Scholar
• COLLINS RH Jr, SHPILBERG O, DROBYSKI WR et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Omni (1997) 15:433–444.
   PubMedGoogle Scholar
• MARR KA, SEIDEL K, SLAVIN MA et al: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood (2000) 96:2055–2061.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated thatadministration of fluconazole had persistent protection against disseminated candidal infections resulting in an increased overall survival in allo-HSCT recipients.
   Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. J. Med. (2002) 346:225–234.
   PubMed Web of Science ®Google Scholar
• GOODRICH JM, BOWDEN RA, FISHER L et al.: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. (1993) 118:173–178.
   PubMed Web of Science ®Google Scholar
• WINSTON DJ, HO WG, BARTONI K et al.: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. (1993) 118:179–184.
   PubMed Web of Science ®Google Scholar
• GOODRICH JM, MORI M, GLEAVES CA et al: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl. I Med. (1991) 325:1601–1607.
   PubMed Web of Science ®Google Scholar
• SCHMIDT GM, HORAK DA, NILAND JC et al.: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl. I Med. (1991) 324:1005–1011.
   PubMed Web of Science ®Google Scholar
• REUSSER P, EINSELE H, LEE J et al.: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood (2002) 99:1159–1164.
   PubMed Web of Science ®Google Scholar
• GIEBEL S, LOCATELLI F, LAMPARELLI T et al.: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102:814–819.
   PubMed Web of Science ®Google Scholar
• RUGGERI L, CAPANNI M, CASUCCI M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 94:333–339.
   PubMed Web of Science ®Google Scholar